2.1
Leniolisib (Joenja, Pharming) is indicated for 'the treatment of activated phosphoinositide 3‑kinase delta (PI3Kδ) syndrome (APDS) in adult and paediatric patients 12 years of age and older'.
2 Information about leniolisib
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for leniolisib.
Price
2.3
The list price of leniolisib is £29,000 per pack of 60 tablets (excluding VAT; company submission).
2.4
The company has a commercial arrangement. This makes leniolisib available to the NHS with a discount. The size of the discount is commercial in confidence.